注射吸毒者中感染HIV的隐匿性丙型肝炎病毒感染率很高。,Archives of Virology

当前位置： X-MOL 学术 › Arch. Virol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

注射吸毒者中感染HIV的隐匿性丙型肝炎病毒感染率很高。
Archives of Virology ( IF 2.5 ) Pub Date : 2019-07-28 , DOI: 10.1007/s00705-019-04353-3
Tahereh Donyavi ₁ , Farah Bokharaei-Salim _{1,

2} , Khadijeh Khanaliha ₃ , Maryam Sheikh ₂ , Mohammad-Navid Bastani ₂ , Najmeh Moradi ₁ , Roghayeh Babaei ₁ , Zahra Habib ₂ , Atousa Fakhim ₄ , Maryam Esghaei ₂

Affiliation

慢性丙型肝炎的病理形式之一是隐匿性HCV感染（OCI），其中血浆标本中没有可检测到的HCV RNA，而PBMC和肝活检标本中存在HCV RNA。这项研究的目的是评估注射毒品使用者（IDU）的HIV阳性人群中OCI的患病率。从2015年4月到2018年8月，该研究共纳入161名感染艾滋病毒的伊朗注射毒品者。从参与者的血浆和PBMC样品中提取病毒RNA，并使用RT巢式PCR和来自两个保守区域（5′-UTR和NS5B）的引物检查HCV RNA的存在。HCV基因分型使用RFLP和测序方法进行。在161名患者中，有134名（83.2％）的抗HCV抗体阳性。所有27例抗HCV阴性的患者血浆中HCV RNA也阴性，但其中5例（18。PBMC中5％的HCV RNA阳性。重要的是，在50例显然已从HCV感染中恢复的患者（18.0％）（即抗HCV阳性和HCV RNA阴性），PBMC中的HCV RNA阳性。总体而言，没有HCV先前感染迹象或从疾病中明显康复的患者中有18.1％患有OCI。OCI患者的HCV基因型如下：5例（35.7％）感染了1a亚型，8例（57.1％）感染了3a亚型，1例（7.1％）感染了4型。，看来OCI在HIV阳性IDU中的流行在伊朗极为重要，并且有可能将全球根除HCV感染的时间推迟到2030年。抗HCV阳性且HCV RNA阴性），PBMC中HCV RNA阳性。总体而言，没有HCV先前感染迹象或从疾病中明显康复的患者中有18.1％患有OCI。OCI患者的HCV基因型如下：5例（35.7％）感染了1a亚型，8例（57.1％）感染了3a亚型，1例（7.1％）感染了4型。，看来OCI在HIV阳性IDU中的流行在伊朗极为重要，并且有可能将全球根除HCV感染的时间推迟到2030年。抗HCV阳性且HCV RNA阴性），PBMC中HCV RNA阳性。总体而言，没有HCV先前感染迹象或从疾病中明显康复的患者中有18.1％患有OCI。OCI患者的HCV基因型如下：5例（35.7％）感染了1a亚型，8例（57.1％）感染了3a亚型，1例（7.1％）感染了4型。，看来OCI在HIV阳性IDU中的流行在伊朗极为重要，并且有可能将全球根除HCV感染的时间推迟到2030年。

"点击查看英文标题和摘要"

High prevalence of occult hepatitis C virus infection in injection drug users with HIV infection.

One of the pathological forms of chronic hepatitis C is occult HCV infection (OCI), in which there is no detectable HCV RNA in plasma specimens but HCV RNA is present in PBMCs and liver biopsy specimens. The aim of this study is to estimate the prevalence of OCI in HIV-positive people who are injection drug users (IDUs). From April 2015 to August 2018, 161 Iranian IDUs with HIV infection enrolled in the study. Viral RNA was extracted from plasma and PBMC samples of participants, and the presence of HCV RNA was examined using RT nested PCR with primers from two conserved regions (5´-UTR and NS5B). HCV genotyping was performed using RFLP and sequencing methods. Of the 161 patients, 134 (83.2%) were positive for anti-HCV antibodies. All 27 patients who were negative for anti-HCV were also negative for HCV RNA in plasma, but five of them (18.5%) were positive for HCV RNA in PBMCs. Importantly, 9 out of 50 patients (18.0%) who apparently had recovered from HCV infection (i.e., were anti-HCV positive and HCV RNA negative) were positive for HCV RNA in PBMCs. Overall, 18.1% of the patients who had no signs of previous HCV infection or had apparently recovered from the disease had OCI. The HCV genotypes of the cases with OCI were as follows: five patients (35.7%) were infected with subtype 1a, eight patients (57.1%) were infected with subtype 3a, and one patient (7.1%) was infected with genotype 4. Thus, it seems that the prevalence of OCI in HIV-positive IDUs is extremely significant in Iran and is likely to delay the global eradication of HCV infection until 2030.

更新日期：2019-07-25

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南